ClinicalTrials.gg
CompletedNCT03981094Updated May 15, 2020

A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants

A Phase 1 interventional study of BMS-986278 and Pirfenidone in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Bristol-Myers Squibb. Completed at 1 site in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-05-15.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2019, 7 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
19th of 21
22 · median 89
Started
2019
the only one that year
Phase 1
5 of 21
none open now
Registered
14th of 21
by date
Lead sponsor
1 of 21
Bristol-Myers Squibb

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 19th largest by enrollment, is the only one that started in 2019, is one of 5 in phase 1, and was the 14th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after administration of a single dose of pirfenidone alone or in combination with BMS-986278

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed .
  • Healthy participant, as determined by no deviation from normal in medical history, physical examination, ECGs, and clinical laboratory determinations.

Exclusion criteria

Exclusion Criteria:

  • Women of child bearing potentia (), pregnant or breastfeeding.
  • History of significant cardiovascular disease.
  • Participants who have smoked or used smoking cessation or nicotine containing products within 3 months of the first dose of study.

Other protocol defined inclusion/exclusion criteria could apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
22 participants (actual)

Study arms

  • Experimental
    BMS-986278

    Drug: BMS-986278

  • Experimental
    Pirfenidone

    Drug: Pirfenidone

  • Experimental
    BMS-986278 + Pirfenidone

    Drug: BMS-986278 · Drug: Pirfenidone

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum observed serum concentration (Cmax) of BMS-986278 and pirfenidone alone or in combination

    Time frame: Up to day 5 of each period (Each period is 7 days; 3 periods total)

  2. Area under the serum concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)] of BMS-986278 and pirfenidone alone or in combinaton

    Time frame: Up to day 5 of each period (Each period is 7 days; 3 periods total)

  3. Area under the plasma concentration-time curve extrapolated to infinity [(AUC(INF)] of BMS-986278 and pirfenidone alone or in combinaton

    Time frame: Up to day 5 of each period (Each period is 7 days; 3 periods total)

Secondary outcomes

  1. Incidence of AEs (adverse events), SAEs (serious adverse events), and AEs leading to discontinuation

    Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)

  2. Number of Participants With Clinically Significant Change in Clinical Laboratory Values

    Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)

  3. Number of Participants With Clinically Significant Change in Vital Signs

    Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)

  4. Number of Participants With Clinically Significant Change in Electrocardiogram (ECG)

    Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)

  5. Number of Participants With Clinically Significant Change in Physical Examination

    Time frame: Up to Day 8 of Period 3 (each period is 7 days; 3 periods total)

  6. Volume of distribution at terminal phase (VzF) of BMS-986278 and metabolite alone or in combination with pirfenidone

    Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)

  7. Time of maximum observed serum concentration (Tmax) of BMS-986278 and metabolite alone or in combination with pirfenidone

    Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)

  8. Elimination half-life (T-HALF) of BMS-986278 and metabolite alone or in combination with pirfenidone

    Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)

  9. Oral clearance (CL/F) of BMS-986278 and metabolite alone or in combination with pirfenidone

    Time frame: Up to Day 5 of period 3 (each period is 7 days; 3 periods total)

  10. Time of maximum observed serum concentration (Tmax) of pirfenidone and metabolite alone or in combination with BMS-986278

    Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)

  11. Elimination half-life (T-HALF) of pirfenidone and metabolite alone or in combination with BMS-986278

    Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)

  12. Oral clearance (CL/F) of pirfenidone and metabolite alone or in combination with BMS-986278

    Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)

  13. Volume of distribution at terminal phase (VzF) Plasma Pharmokinetics of pirfenidone and metabolite alone or in combination with BMS-986278

    Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)

  14. Renal clearance (Clr) in Urine of pirfenidone alone or in combination with BMS-986278

    Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)

  15. Cumulative amount recovered in urine [Ae(0-T)] of pirfenidone alone or in combination with BMS-986278

    Time frame: Up to Day 5 of Period 3 (each period is 7 days; 3 periods total)

07

Study locations

1 site
  • PRA Health Sciences - Salt Lake
    Salt Lake City, Utah 84124, United States
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Jul 2019, 2 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 2 months is below that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 21, 2019
First posted
Jun 10, 2019
StartActual
May 10, 2019
Primary completionActual
Jul 27, 2019
CompletionActual
Jul 30, 2019
Last update
May 15, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 15, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03981094
Responsible party
Sponsor
First posted
Jun 10, 2019
Start date
May 10, 2019
Primary completion
Jul 27, 2019
Completion
Jul 30, 2019
Last update
May 15, 2020

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Admilparant · Pirfenidone

Start the discussion